Nalaganje...

The Promise of Chimeric Antigen Receptor Engineered T cells in the Treatment of Hematologic Malignancies

Relapsed and refractory hematologic malignancies have a very poor prognosis. Chimeric antigen receptor (CAR) T cells are emerging as a powerful therapy in this setting. Early clinical trials of genetically modified T cells for the treatment of non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Cancer J
Main Authors: Nagle, Sarah J., Garfall, Alfred L., Stadtmauer, Edward A.
Format: Artigo
Jezik:Inglês
Izdano: 2016
Teme:
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4742356/
https://ncbi.nlm.nih.gov/pubmed/26841014
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/PPO.0000000000000166
Oznake: Označite
Brez oznak, prvi označite!